Nymox Pharmaceutical Corporation (NYMX) Stock Analysis
DELISTED 2023
What happened to Nymox Pharmaceutical Corporation (NYMX) stock?
Nymox Pharmaceutical Corporation (NYMX) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nymox Pharmaceutical Corporation (NYMX) trades at $0.1999. Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing treatments for aging-related conditions. Their lead drug candidate, Fexapotide Triflutate, targets benign prostatic hyperplasia and other indications. Market cap: $18.2M, Sector: Healthcare.
Last analyzed: May 5, 2026Analyst Coverage for NYMX: NYMX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NYMX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
NYMX: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Nymox Pharmaceutical Corporation (NYMX) Healthcare & Pipeline Overview
Nymox Pharmaceutical Corporation is a biopharmaceutical firm concentrating on therapeutics for the aging population, with its primary focus on Fexapotide Triflutate (NX-1207) for benign prostatic hyperplasia. The company also develops diagnostic tests, positioning it within the broader biotechnology sector focused on age-related diseases.
What Is the Investment Thesis for NYMX?
Nymox Pharmaceutical Corporation presents a speculative investment opportunity centered on the potential success of Fexapotide Triflutate (NX-1207). The drug's Phase III clinical trial results for benign prostatic hyperplasia (BPH) are a key value driver. Positive outcomes and subsequent regulatory approvals could significantly increase the company's market capitalization. Growth catalysts include the advancement of NX-1207 through further clinical trials for prostate cancer and hepatocellular carcinoma. The company's diagnostic products, such as AlzheimAlert, offer a supplementary revenue stream. However, the company's small size, limited resources, and reliance on a single lead drug candidate present significant risks. Investor sentiment and regulatory decisions will heavily influence the stock's performance.
Based on FMP financials and quantitative analysis
NYMX Key Highlights
Fexapotide Triflutate (NX-1207) has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia (BPH).
- NX-1207 is in Phase II clinical trials for low grade localized prostate cancer.
- NX-1207 is in preclinical studies for hepatocellular carcinoma.
- Nymox develops and markets NicAlert and TobacAlert tests for detecting tobacco use.
- AlzheimAlert, a proprietary urine assay, aids in the diagnosis of Alzheimer's disease.
Who Are NYMX's Competitors?
NYMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NYMX's Key Strengths?
Proprietary drug candidate (Fexapotide Triflutate) in late-stage clinical development.
- Diagnostic tests provide revenue diversification.
- Focus on addressing unmet needs in the aging population.
- Experienced management team.
What Are NYMX's Weaknesses?
Limited financial resources.
- Reliance on a single lead drug candidate.
- Small number of employees.
- High regulatory risk associated with drug development.
What Could Drive NYMX Stock Higher?
Regulatory review and potential approval of Fexapotide Triflutate for BPH.
- Progression of NX-1207 through clinical trials for prostate cancer.
- Preclinical studies of NX-1207 for hepatocellular carcinoma.
- Expansion of commercialization efforts for diagnostic tests.
What Are the Key Risks for NYMX?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Fexapotide Triflutate.
- Regulatory setbacks or delays.
- Competition from established pharmaceutical companies.
- Difficulty securing funding.
- Product liability claims.
What Are the Growth Opportunities for NYMX?
- Advancement of Fexapotide Triflutate (NX-1207) for BPH: Nymox's primary growth opportunity lies in securing regulatory approval and commercializing NX-1207 for the treatment of BPH. Successful completion of ongoing clinical trials and positive regulatory outcomes are critical for realizing this opportunity. The timeline for potential market entry depends on regulatory review processes, which can take several years.
- Expansion into Prostate Cancer Treatment: Nymox is conducting Phase II clinical trials for NX-1207 as a treatment for low-grade localized prostate cancer. The prostate cancer therapeutics market is substantial and growing, presenting a significant opportunity for Nymox. Positive clinical trial results could lead to regulatory approval and market entry, expanding the company's revenue streams. The timeline for this opportunity depends on the progress and outcomes of the Phase II trials.
- Development of Hepatocellular Carcinoma Treatment: Nymox is in preclinical studies for NX-1207 as a treatment for hepatocellular carcinoma. The hepatocellular carcinoma treatment market is expanding due to the increasing prevalence of liver cancer. Successful preclinical studies could lead to clinical trials and eventual market entry, providing a long-term growth opportunity for Nymox. The timeline for this opportunity is uncertain, as it depends on the outcomes of preclinical studies and subsequent clinical trials.
- Commercialization of Diagnostic Products: Nymox develops and markets diagnostic tests, including NicAlert, TobacAlert, and AlzheimAlert. Expanding the commercialization of these products represents a growth opportunity for the company. Increased adoption of these tests by healthcare providers and consumers could generate additional revenue streams. The timeline for this opportunity depends on marketing efforts and distribution agreements.
- Strategic Partnerships and Licensing Agreements: Nymox could pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its drug candidates and diagnostic products. Collaborating with larger pharmaceutical companies or research institutions could provide access to additional funding, expertise, and resources. These partnerships could expedite the regulatory approval process and expand market reach. The timeline for this opportunity depends on the company's ability to identify and secure suitable partners.
What Are NYMX's Competitive Advantages?
- Proprietary drug candidate (Fexapotide Triflutate) with potential for market exclusivity.
- Diagnostic tests (NicAlert, TobacAlert, AlzheimAlert) provide niche revenue streams.
- Intellectual property protection through patents and trademarks.
- Established research and development capabilities in the field of aging-related diseases.
What Does NYMX Do?
Founded in 1989 and headquartered in Nassau, Bahamas, Nymox Pharmaceutical Corporation is a biopharmaceutical company dedicated to the research and development of innovative treatments for conditions affecting the aging population. The company's lead drug candidate, Fexapotide Triflutate (NX-1207), has undergone Phase III clinical trials for benign prostatic hyperplasia (BPH). Additionally, NX-1207 has completed Phase II clinical trials for low-grade localized prostate cancer and is in preclinical studies for hepatocellular carcinoma. Beyond its pharmaceutical development, Nymox also offers diagnostic tests, including NicAlert and TobacAlert, which detect tobacco use through urine or saliva samples. AlzheimAlert, a proprietary urine assay, aids physicians in diagnosing Alzheimer's disease. Nymox is also involved in researching and developing drug treatments for Alzheimer's disease, reflecting its commitment to addressing significant healthcare challenges associated with aging. The company operates internationally, targeting markets in Canada, the United States, and Europe. With a small team, Nymox focuses on advancing its clinical programs and commercializing its diagnostic products.
What Products and Services Does NYMX Offer?
- Researches and develops drugs for the aging population.
- Develops Fexapotide Triflutate (NX-1207) for benign prostatic hyperplasia (BPH).
- Conducts clinical trials for prostate cancer and hepatocellular carcinoma treatments.
- Develops and markets NicAlert and TobacAlert tests for tobacco use detection.
- Offers AlzheimAlert, a urine assay for Alzheimer's disease diagnosis.
- Researches and develops drug treatments for Alzheimer's disease.
How Does NYMX Make Money?
- Develops and seeks to commercialize pharmaceutical products.
- Generates revenue through the sale of diagnostic tests.
- Aims to license or partner its drug candidates for further development and commercialization.
- Secures funding through equity offerings and potential grants.
What Industry Does NYMX Operate In?
Nymox Pharmaceutical Corporation operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The company focuses on developing treatments for age-related diseases, aligning with the growing demand for healthcare solutions for the aging population. Competition in the biotechnology sector is intense, with numerous companies vying for market share in the treatment of BPH, prostate cancer, and Alzheimer's disease. Nymox's success depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate the efficacy and safety of its drug candidates.
Who Are NYMX's Key Customers?
- Healthcare providers (doctors, hospitals, clinics).
- Patients seeking treatment for BPH, prostate cancer, and Alzheimer's disease.
- Consumers interested in tobacco use detection tests.
- Research institutions and pharmaceutical companies (potential partners).
Company Profile
Nymox Pharmaceutical Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Nassau, BS. The company is led by CEO Paul Averback DABP,. NYMX has traded publicly since 1997.
Financial Health
Nymox Pharmaceutical Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Nymox Pharmaceutical Corporation stands at 90.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -20.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -35.9%, the inverse of the P/E and a quick read on earnings relative to price.
NYMX Valuation & Market Position
With a $18.2M market cap, Nymox Pharmaceutical Corporation sits in the micro-cap segment of the market.
NYMX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary drug candidate (Fexapotide Triflutate) in late-stage clinical development.
- Diagnostic tests provide revenue diversification.
- Focus on addressing unmet needs in the aging population.
- Experienced management team.
Bear Case
- Limited financial resources.
- Reliance on a single lead drug candidate.
- Small number of employees.
- High regulatory risk associated with drug development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NYMX Latest News
No recent news available for NYMX.
Leadership: Paul Averback DABP,
CEO
Paul Averback is the CEO of Nymox Pharmaceutical Corporation. He is a physician and has been involved in the pharmaceutical industry for many years. His background includes experience in clinical research, drug development, and regulatory affairs. He is a Diplomate of the American Board of Pathology (DABP). He has overseen the development of Nymox's key drug candidates and diagnostic products. His expertise is crucial for guiding the company through the complex regulatory landscape and clinical trial processes.
Track Record: Under Paul Averback's leadership, Nymox has advanced Fexapotide Triflutate (NX-1207) through Phase III clinical trials for BPH. He has also overseen the development and commercialization of diagnostic tests such as NicAlert and AlzheimAlert. His strategic decisions have focused on advancing the clinical pipeline and securing funding for the company's research and development programs.
Common Questions About NYMX (Healthcare)
What happened to Nymox Pharmaceutical Corporation (NYMX) stock?
Nymox Pharmaceutical Corporation (NYMX) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
Can I still buy NYMX shares?
No. NYMX stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for NYMX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NYMX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Nymox Pharmaceutical Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Nymox Pharmaceutical Corporation do?
Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing and commercializing innovative treatments and diagnostics for the aging population. Its lead drug candidate, Fexapotide Triflutate (NX-1207), is in late-stage clinical development for benign prostatic hyperplasia (BPH).
What do analysts say about NYMX stock?
Analyst coverage of Nymox Pharmaceutical Corporation (NYMX) is limited due to its small market capitalization and speculative nature. The stock's performance is heavily influenced by clinical trial results and regulatory decisions related to Fexapotide Triflutate (NX-1207). Key valuation metrics are difficult to assess due to the company's limited revenue and reliance on future product approvals.
What are the main risks for NYMX?
Nymox Pharmaceutical Corporation faces several key risks, including clinical trial failures, regulatory setbacks, competition from established pharmaceutical companies, and difficulty securing funding. The company's reliance on a single lead drug candidate (Fexapotide Triflutate) makes it particularly vulnerable to negative clinical trial results or regulatory decisions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.
- Limited analyst coverage and financial data may impact the accuracy of the assessment.